secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001193125-25-003519
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks reports $324M cash, provides 2025-2026 pipeline milestones and cash runway into 2H-2027
--------------------------------------------------------------------------------

- Cash resources ~$324M as of Dec 31, 2024, plus $25M milestone from Jazz expected in Q1 2025.
- Cash runway expected to fund planned operations into 2H-2027, including anticipated regulatory milestone payments.
- Phase 3 HERIZON-GEA-01 top-line results for zanidatamab in first-line GEA expected 2Q 2025; sBLA later in 2025.
- Potential EU approval for zanidatamab in second-line BTC as early as 2Q 2025; China NMPA decision as early as 2H 2025.
- IND applications for ZW220, ZW251 in solid tumors in 2025; ZW209 and ZW1528 (AIID) INDs in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312525003519/0001193125-25-003519-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312525003519/d894323d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-003519

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer